Screener
BridgeBio Pharma BBIO Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026. Open the filing →
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
FAQ
- What is BridgeBio Pharma's finite-lived intangible assets - expected amortization expense (year one)?
- BridgeBio Pharma (BBIO) reported finite-lived intangible assets - expected amortization expense (year one) of $2.9M in Q2 2026.
- What does finite-lived intangible assets - expected amortization expense (year one) mean?
- This metric forecasts the amortization expense expected to be recognized in the upcoming fiscal year for intangible assets with finite useful lives. It provides visibility into the non-cash earnings impact of previously acquired intangible assets. Analysts use this to refine future earnings projections and cash flow models.
Ask your AI about BridgeBio Pharma's finite-lived intangible assets - expected amortization expense (year one).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude